Medtronic has secured the US Food and Drug Administration (FDA) approval for its Claria MRI Quad Cardiac Resynchronisation Therapy Defibrillator (CRT-D) SureScan device for patients with heart failure.

Approved for scanning in both 1.5 and 3 Tesla (T) magnetic resonance imaging (MRI) machines, the Claria device features a new algorithm, EffectivCRT, which automatically customises the therapy to individual patients by adjusting pacing rates.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Arrhythmia Institute of the Valley Health System electrophysiology laboratory director Suneet Mittal said: "Until now, CRT devices have shown only whether a pacing pulse was sent, but we have not been able to determine if that stimulation actually improves the heart's pumping ability.

"The device is incorporated with the AdaptivCRT algorithm which minimises the chance of a patient’s heart failure readmission by 59% and has reduced 46% atrial fibrillation risk."

"With the Claria device, physicians are now able to verify the effectiveness of left ventricular pacing, which is especially beneficial for improving outcomes in patients with atrial fibrillation, who have been difficult to treat because this irregular and rapid heartbeat often interferes with the delivery of effective CRT."

Among other features, the device is incorporated with the AdaptivCRT algorithm which minimises the chance of a patient’s heart failure readmission by 59% and has reduced 46% atrial fibrillation risk.

The Claria device includes the automated in-office VectorExpress test which decreases lead programing to two minutes and reveals clinically actionable information to enable physicians choose optimal pacing configurations for each patient.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The Attain Perfoma MRI SureScan Quadripolar Leads features short bipolar spacing to reduce phrenic nerve stimulation occurrence, steroid on all electrodes, and three shapes to accommodate different patient anatomies.

The device also features SureScan MR-conditional labeling for full-body scans without positioning restrictions.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact